ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for back of the eye disease, today announced that it will be presenting at several key investor meetings over the next few weeks and months.

The announced roadshow plans follow the Company’s introduction of its new drug development pipeline first presented during last Friday’s ThromboGenics Research & Development Investor Meeting in London.

Over the past 18 months, ThromboGenics has developed a world class pipeline of disease modifying drug candidates for the treatment of diabetic eye disease. The pipeline consists of THR-409 (ocriplasmin), THR-317 (anti-PlGF), THR-149 (plasma kallikrein inhibitor), which has resulted from a research collaboration with Bicycle Therapeutics, and THR-687 (integrin receptor antagonist), which was recently in-licensed from Galapagos. With that, ThromboGenics will initiate several new clinical trials over the next 3-4 years, starting in 2016.

Next to its ambitious plans in ophthalmology, ThromboGenics is also progressing its commitments in oncology via its spin out Oncurious nv, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors. Last week’s announcement of the Oncurious partnership with NMTRC in the US, is a last step in the preparative work before initiating a Phase I/IIa clinical program with TB-403 for the treatment of medulloblastoma, a rare, life-threatening pediatric cancer. Further announcements are awaited.

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for back of the eye disease, with a focus on diabetic eye disease.

Diabetic retinopathy (DR) and diabetic macular edema (DME) are the fastest growing segments of the overall ophthalmology market, which is forecast to increase in value from an estimated $1.6 billion in 2015 to $4.2 billion in 2023, or a 16% CAGR.

ThromboGenics pioneered the new drug category of pharmacological vitreolysis with Jetrea® (ocriplasmin). Jetrea® is now approved for the treatment of vitreomacular traction in over 54 countries worldwide. Alcon, a division of Novartis, commercializes Jetrea® outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties.
The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.